JANX Janux Therapeutics Inc
Price (delayed)
$28.25
Market cap
$1.67B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.28
Enterprise value
$1.26B
Highlights
JANX's equity has surged by 197% year-on-year and by 56% since the previous quarter
The quick ratio has soared by 122% year-on-year and by 53% since the previous quarter
The revenue has grown by 31% YoY but it has contracted by 19% from the previous quarter
JANX's gross profit is up by 31% YoY but it is down by 19% QoQ
The net income has contracted by 18% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of JANX
Market
Valuations
Earnings
Shares outstanding
59.11M
Market cap
$1.67B
Enterprise value
$1.26B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.45
Price to sales (P/S)
143.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
119.13
Revenue
$10.59M
Gross profit
$10.59M
Operating income
-$98.85M
Net income
-$68.99M
EBIT
-$68.99M
EBITDA
-$66.93M
Free cash flow
-$44.17M
Per share
Balance sheet
Liquidity
EPS
-$1.28
EPS diluted
-$1.28
Free cash flow per share
-$0.82
Book value per share
$19.49
Revenue per share
$0.2
TBVPS
$19.75
Total assets
$1.06B
Total liabilities
$38.74M
Debt
$23.03M
Equity
$1.02B
Working capital
$1.02B
Debt to equity
0.02
Current ratio
59.21
Quick ratio
58.77
Net debt/EBITDA
6.1
Margins
Efficiency
Dividend
EBITDA margin
-632.2%
Gross margin
100%
Net margin
-651.6%
Operating margin
-933.6%
Return on assets
-8.8%
Return on equity
-9.2%
Return on invested capital
-11.1%
Return on capital employed
-6.6%
Return on sales
-651.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JANX stock price
How has the Janux Therapeutics stock price performed over time
Intraday
5.37%
1 week
-6.21%
1 month
-14.11%
1 year
-21.24%
YTD
-47.24%
QTD
4.63%
Financial performance
How have Janux Therapeutics's revenue and profit performed over time
Revenue
$10.59M
Gross profit
$10.59M
Operating income
-$98.85M
Net income
-$68.99M
Gross margin
100%
Net margin
-651.6%
The operating margin has contracted by 42% from the previous quarter and by 3.4% YoY
Janux Therapeutics's net margin has decreased by 40% QoQ but it has increased by 10% YoY
JANX's operating income is down by 35% year-on-year and by 15% since the previous quarter
The revenue has grown by 31% YoY but it has contracted by 19% from the previous quarter
Growth
What is Janux Therapeutics's growth rate over time
Valuation
What is Janux Therapeutics stock price valuation
P/E
N/A
P/B
1.45
P/S
143.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
119.13
The EPS has contracted by 10% from the previous quarter but it has grown by 3% YoY
JANX's equity has surged by 197% year-on-year and by 56% since the previous quarter
JANX's P/B is 57% below its last 4 quarters average of 3.2
The P/S is 37% less than the last 4 quarters average of 216.6
The revenue has grown by 31% YoY but it has contracted by 19% from the previous quarter
Efficiency
How efficient is Janux Therapeutics business performance
JANX's return on equity is up by 49% year-on-year and by 12% since the previous quarter
The ROA has grown by 45% YoY and by 11% from the previous quarter
The ROS has contracted by 40% from the previous quarter but it has grown by 10% YoY
The return on invested capital is up by 34% year-on-year
Dividends
What is JANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JANX.
Financial health
How did Janux Therapeutics financials performed over time
Janux Therapeutics's total assets has surged by 179% YoY and by 53% QoQ
The quick ratio has soared by 122% year-on-year and by 53% since the previous quarter
Janux Therapeutics's debt is 98% lower than its equity
JANX's equity has surged by 197% year-on-year and by 56% since the previous quarter
Janux Therapeutics's debt to equity has plunged by 71% YoY and by 50% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.